Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.AEZS

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:AEZS - Post Discussion

COSCIENS Biopharma Inc > Re: Strategic acquisitions
View:
Post by Hopeforthebest on Jul 12, 2024 5:37pm

Re: Strategic acquisitions

Proph copied - The Edmonton facility was installed and commissioned by the end of Q1 as expected. Then they went to the 'fine tuning' phase and have had multiple production runs which were "almost completed" as of the April 29, 2024 news release. The product could be available by year end with Health Canada approval. The Edmonton facility already has Health Canada approval for natural products so it could be a streamlined process. Also, as noted in the Feb. news release, the oat beta glucan chewy product also received Health Canada approval and is expected to be launched in the second half of this year. Health Canada is very familiar with the company and major global brands also rely on the company's facilities.

The commisioning of the PGX scales is NOT finsished until the fine tuning is completed and they prove that they can make a consistent product, then only then commissioning is complete and then and only then can they apply for a Health Canada approval on the product they can consistently produce. The Health canada approval is based on a generic product.

Secondly as incorrectly stated in teh news release, the original completiondate of the commssioning for the PGX scale up was at the end of 2023 not q1 2024.

This just shows how gagnon continues to time lines dates etc to suit his incompetency. We are now 7 plus months past due his original date that HE set.


Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities